Multiple Sclerosis and Female Sexual Dysfunction: Impact of Disease Severity and Duration

2020 ◽  
pp. 33-37
Author(s):  
O.I. Nehrych ◽  
◽  
V.I. Pyrohova ◽  

Despite a lot of studies of sexual dysfunction there are still no consistent data about the prevalence and characteristics of sexual dysfunction among women with MS, especially it terms of multiple sclerosis severity and duration. The objective: was to determine the prevalence of various SD symptoms among female MS patients, depending on the age and severity of the disease, and evaluate SD impact on quality of life. Materials and methods. The study population includes 116 female patients with MS (McDonald’s criteria, 2010). Health – related quality of life was measured by the Multiple Sclerosis Quality of Life Questionnaire (MSQOL-54). Sexual dysfunction was assessed with the Sexual Function Index for Women with Multiple Sclerosis Questionnaire. Results. A direct average correlation between satisfaction with sexual life and relationships; sexual activity and arousal; discomfort and pain during sexual intercourse; direct impact of multiple sclerosis on sexual life and total quality of life, physical health component, mental health component was established (р<0.05). The prevalence of sexual dysfunction increases with the age and disease duration. Conclusions. Our data confirm that SD is common symptom in women with MS and significantly affect their quality of life. Key words: multiple sclerosis, female sexual dysfunction.

2008 ◽  
Vol 14 (8) ◽  
pp. 1131-1136 ◽  
Author(s):  
DK Tepavcevic ◽  
J Kostic ◽  
ID Basuroski ◽  
N Stojsavljevic ◽  
T Pekmezovic ◽  
...  

Objective Sexual dysfunction (SD) is a common but often overlooked symptom in multiple sclerosis (MS). The aim of this study was to estimate the frequency, type, and intensity of SD in our patients with MS and to investigate its influence on all the domains of quality of life. Methods The study population comprised a cohort of 109 patients with MS (McDonald's criteria, 2001). SD was quantified by a Szasz sexual functioning scale. Health-related quality of life was measured by a disease-specific instrument MSQoL-54 (Serbian version). Results The presence of at least one symptom of SD was found in about 84% of the men and in 85% of the women. The main complaints in women were reduced libido, difficulties in achieving orgasm, and decreased vaginal lubrication; in men, the main complaints were reduced libido, incomplete erections, and premature ejaculation. In women, statistically significant negative correlations between the presence and level of SD and quality of life domains were reached for all subscales ( P < 0.01), except for the Pain subscale ( P = 0.112). In men, negative correlations were also observed for all domains, but they were statistically significant for physical health, physical role limitations, social function, health distress, sexual function, and sexual function satisfaction ( P < 0.01). We found that the presence of all the analyzed types of sexual problems statistically significantly lowered scores on the sexual function and the sexual function satisfaction subscales in both men and women ( P < 0.01). The most prominent impact on both domains was observed for the total loss of erection in men and for anorgasmia in women. Conclusions Our results reveal that frequent occurrence of SD in MS patients prominently affects all aspects of their quality of life.


2011 ◽  
Vol 17 (11) ◽  
pp. 1341-1350 ◽  
Author(s):  
X Montalban ◽  
G Comi ◽  
P O’Connor ◽  
SM Gold ◽  
A de Vera ◽  
...  

Background: Health-related quality of life (HRQoL) worsens with multiple sclerosis (MS) relapses and disease progression. Common symptoms including depression and fatigue may contribute to poor HRQoL. Objectives: To report exploratory analyses assessing the impact of fingolimod (FTY720) on HRQoL and depression in a phase II study of relapsing MS. Methods: The Hamburg Quality of Life Questionnaire in MS (HAQUAMS) and Beck Depression Inventory second edition (BDI-II) scores were assessed during a 6-month, placebo-controlled study and optional extension. Results: HAQUAMS total score improved with fingolimod and worsened with placebo. Mean score change from baseline to month 6 was −0.02 with fingolimod 1.25 mg ( p < 0.05 versus placebo), −0.01 with fingolimod 5.0 mg and + 0.12 with placebo. Categorical data supported a clinically important effect of fingolimod on HRQoL. Fingolimod 1.25 mg was also beneficial over placebo in the fatigue/thinking HAQUAMS sub-domain ( p < 0.05 versus placebo). Change in mean BDI-II scores from baseline to month 6 and the proportion of patients with BDI-II scores indicative of clinical depression favored fingolimod 1.25 mg over placebo ( p < 0.05 for both). At month 4, mean BDI-II and HAQUAMS total scores appeared to be maintained in fingolimod-treated patients. Conclusion: Fingolimod 1.25 mg may improve HRQoL and depression at 6 onths compared with placebo in patients with relapsing MS.


2020 ◽  
pp. 0000-0000
Author(s):  
Ricardo N. Alonso ◽  
Maria B. Eizaguirre ◽  
Leila Cohen ◽  
Cecilia Quarracino ◽  
Berenice Silva ◽  
...  

Abstract Background: Scales to assess disability in multiple sclerosis (MS) rarely provides reliable data on the actual global impairment. Upper limbs (UL) dysfunction is usually overlooked, which has a negative impact on the patient's well-being. Objectives: 1) to analyze the association between UL dexterity, lower limbs (LL) speed and the EDSS score. 2) To analyze the difference in UL dexterity between patients with EDSS &lt;5 and ≥5. 3) To study the association that UL dexterity, LL speed and the EDSS score have with both health-related quality of life measurements and depression. Methods: Our sample included 140 adults with MS. They were evaluated using the Nine-Hole Peg Test, the Timed 25-Foot Walk test, the EDSS, the Multiple Sclerosis International Quality of Life questionnaire (MusiQol), and the Beck Depression Inventory. We conducted a thorough descriptive-analytical research using Spearman's correlation, multiple linear regression and structural equation modeling. Results: UL dexterity was more closely related to the EDSS than LL speed (r: 0.43 vs. 0.29, R2: 0.38). UL dexterity was greatest in patients with EDSS &lt;5 (P &lt; .001). Moreover, UL dexterity was negatively associated with EDSS and the MusiQol (rS: between −0.557 and −0.358, P &lt; .05). The correlation that depression has with loss of dexterity in UL was higher than the one it has with LL speed (0.098 vs 0.066, t &gt; 1.96). Conclusions: UL dexterity is associated and global disability, depression, and health-related quality of life. We advocate for the assessment of UL dexterity during MS patients' consultations to adopt a better approach to their functional impairment.


2013 ◽  
Vol 36 (12) ◽  
pp. 987-992 ◽  
Author(s):  
Marianna Vitkova ◽  
Jaroslav Rosenberger ◽  
Martina Krokavcova ◽  
Jarmila Szilasiova ◽  
Zuzana Gdovinova ◽  
...  

2009 ◽  
Vol 15 (10) ◽  
pp. 1239-1249 ◽  
Author(s):  
JM Wesson ◽  
JA Cooper ◽  
LS Jehle ◽  
SN Lockhart ◽  
K. Draney ◽  
...  

Addressing health-related quality of life is considered a desirable component of routine care for patients with multiple sclerosis. However, use of available health-related quality of life surveys is not part of routine multiple sclerosis care, possibly due to administration, scoring, and interpretation challenges presented by available questionnaires. The 25-item Functional Index for Living with Multiple Sclerosis (FILMS) questionnaire was developed and validated to allow providers to monitor and easily apply health-related quality of life information to the patient encounter. The development and pilot test processes and the results of the validation study are reported here. Convergent validity, internal consistency reliability, and test—retest reproducibility were evaluated. Strong correlations of Functional Index for Living with Multiple Sclerosis subscales with control questionnaires were demonstrated by Pearson’s correlation coefficients from 0.73 to 0.88. Internal consistency reliabilities ranged from 0.80 to 0.90, demonstrating that items were grouped into the appropriate subscale domains and that the subscale domains and the questionnaire as a whole exhibited good directionality. Test—retest reproducibility was 0.91.


2018 ◽  
Vol 25 (11) ◽  
pp. 1539-1542
Author(s):  
Georgina Baker ◽  
Krishnan Padmakumari Sivaraman Nair ◽  
Kathleen Baster ◽  
Rosalba Rosato ◽  
Alessandra Solari

Background: Multiple Sclerosis Quality-of-Life Questionnaire-54 (MSQoL-54) is a disease-specific instrument for assessing health-related quality of life (HRQoL). Due to the number of items, the time taken to complete it is long. A shorter 29-item version, Multiple Sclerosis Quality-of-Life Questionnaire-29 (MSQoL-29) is yet to be evaluated in English. Objective: To assess reliability and acceptability of English version of MSQoL-29. Methods: Among 100 participants with MS who first completed both MSQoL-54 and MSQoL-29, 91 completed MSQoL-29 after 4–8 weeks. We looked for internal consistency (Cronbach’s alpha), acceptability, reliability (intraclass correlation coefficients (ICCs)) and agreement (Bland–Altman plots). Results: ICCs were strongly positive between MSQoL-54 and MSQoL-29 (Physical Health Composite (PHC) –ICC = 0.914, confidence interval (CI) = 0.872–0.942; Mental Health Composite (MHC) – ICC = 0.875, CI = 0.814–0.916) and between the two MSQoL-29 (PHC – ICC = 0.970, CI = 0.955–0.980; MHC – ICC = 0.937, CI = 0.904–0.958). On Bland–Altman plots, the MSQoL-29 scores of 95% of participants during two visits were within the limits of agreement (LOAs). Time taken to complete MSQoL-29 was 7.2 ± 2.9 minutes and MSQoL-54 was 19.79 ± 5.4 minutes ( p = 0.0001). Conclusion: MSQoL-29 has good test–retest reliability in English-speaking population and was quicker to complete.


2010 ◽  
Vol 12 (2) ◽  
pp. 83-91 ◽  
Author(s):  
Vivek S. Pawar ◽  
Gauri Pawar ◽  
Lesley-Ann Miller ◽  
Iftekhar Kalsekar ◽  
Jan Kavookjian ◽  
...  

The aim of this study was to evaluate the impact of visual impairment on health-related quality of life (HRQOL) in patients with multiple sclerosis (MS). Patients at an outpatient MS clinic were asked to complete a battery of patient-reported outcome questionnaires. Health-related quality of life was measured using the Hamburg Quality of Life Questionnaire for Multiple Sclerosis (HAQUAMS), while visual impairment was measured using the Visual Function Questionnaire (VFQ). Hierarchical regression was used to determine the relative contribution of visual impairment to HRQOL. Usable responses were obtained for 116 MS patients. Those with higher levels of visual impairment (lower scores on the VFQ) reported significantly lower HRQOL (β = –0.01, P = .0007). Visual impairment also explained an additional 4% variance in the HRQOL scores, independent of disability and depression (ΔR2 = 0.04, F7,108 = 36.58). Overall, disability was the strongest predictor of HRQOL, explaining over 60% of the variation in HRQOL scores. The model explained 70% of the total variance in HRQOL. Given the prevalence of visual impairment and its influence on overall HRQOL, MS patients should be routinely screened using standard ophthalmic examination procedures or self-administered questionnaires such as the VFQ.


2006 ◽  
Vol 12 (2) ◽  
pp. 209-211 ◽  
Author(s):  
M. Demirkiran ◽  
Y. Sarica ◽  
S. Uguz ◽  
D. Yerdelen ◽  
K. Aslan

Objective Sexual dysfunction (SD) severely affects the quality of life in patients with multiple sclerosis (MS). The aim of this study is to investigate the type and frequency of sexual complaints in MS patients, to analyse their relationship to various clinical and psychosocial variables and to clarify the differences between MS patients with and without SD. Methods Thirty-five relapsing-remitting (RR), nine secondary progressive and seven primary progressive MS patients were included in this study. A structured face-to-face interview regarding sexual function and other physical problems which may interfere with sexual functioning was administered to each patient. They also filled out Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 (MSISQ-19), which includes items for primary (direct physical), secondary (indirect physical) and tertiary (psychosocial) causes of SD. Disability, cognitive functions and psychological functioning were also evaluated. Results Forty-one patients (80.4%) reported primary SD; decreased libido was the most frequent complaint (80.5%). These patients were older and more disabled, however 39% had low disability scores. SD was a common problem for both men and women. Patients with RRMS were affected less in all items of primary SD. Several items of secondary SD-problems with memory and concentration, bladder symptoms, bowel symptoms-showed correlation with different items of primary SD; these were altered genital sensation, decreased libido, increased time for arousal, decreased lubrication/difficulties with erection. Total MSISQ-19 scores were correlated with disease duration, age, disability, disease course, Beck depression scale, temporary and long-standing anxiety and low level of education. Conclusion SD is an underestimated, common symptom of MS. It may occur in MS even in the absence of severe disability. Physicians’ awareness of this problem may help to bring about appropriate treatments and management, and improve the quality of life for these patients.


2013 ◽  
Vol 20 (5) ◽  
pp. 610-616 ◽  
Author(s):  
Laura C Schairer ◽  
Frederick W Foley ◽  
Vance Zemon ◽  
Tuula Tyry ◽  
Denise Campagnolo ◽  
...  

Background: Sexual dysfunction is a prevalent symptom in multiple sclerosis (MS) that may affect patients’ health-related quality of life (HrQoL). Objective: The objective of this paper is to examine the impact of sexual dysfunction on HrQoL in a large national sample using The Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 (MSISQ-19). Methods: Participants were recruited from a large MS registry, the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry. Participants self-reported demographic information and completed the Patient Determined Disease Steps (PDDS), MSISQ-19, and the Short Form-12 (SF-12). Results: The study population included 6183 persons (mean age: 50.6, SD = 9.6; 74.7% female, 42.3% currently employed). Using multivariate hierarchical regression analyses, all variables excluding gender predicted both the physical component summary (PCS-12) and the mental component summary (MCS-12) of the SF-12. Scores on the MSISQ-19 uniquely accounted for 3% of the variance in PCS-12 scores while disability level, as measured by PDDS, accounted for 31% of the variance. Conversely, MSISQ-19 scores uniquely accounted for 13% of the variance in MCS-12 scores, whereas disability level accounted for less than 1% of the variance. Conclusion: In patients with MS, sexual dysfunction has a much larger detrimental impact on the mental health aspects of HrQoL than severity of physical disability.


2009 ◽  
Vol 100 (3) ◽  
pp. 148-155 ◽  
Author(s):  
L. E. M. A. Pfennings ◽  
H. M. Ploeg ◽  
L. Cohen ◽  
I. Bramsen ◽  
C. H. Polman ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document